CD274 and cancer: Despite the success of PD-1/PD-L1 antagonists, the vast majority of cancer patients are either innately resistant (up to 60% of patients) or acquire a refractory phenotype during treatment, resulting in durable responses in only about 20% of treatment eligible patients (8–10).